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a b s t r a c t
Given the pivotal role of monocyte-derived dendritic cells (DCs) in determining the magnitude of the
antiviral innate immune response, we sought to determine whether Usutu virus (USUV) and West Nile
virus (WNV) lineages (L)1 and L2 can infect DCs and affect the rate of type I interferon (IFN) activation.
The sensitivity of these viruses to types I and III IFNs was also compared. We found that USUV can infect
DCs, induce higher antiviral activities, IFN alpha subtypes and the IFN stimulated gene (ISG)15 pathway,
and is more sensitive to types I and III IFNs than WNVs. In contrast, we conﬁrmed that IFN alpha/beta
subtypes were more effective against WNV L2 than WNV L1. However, the replication kinetics, induction
of IFN alpha subtypes and ISGs in DCs and the sensitivity to IFN lambda 1–3 did not differ between WNV
L1 and L2.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Usutu virus (USUV) and West Nile virus (WNV) belong to the
family Flaviviridae. They are maintained in nature by bird–mosquito
(mainly of the genus Culex) transmission cycles and incidental
infections of mammals such as humans and horses, which are
considered dead-end hosts (Hubálek et al., 2014). In Europe, the
circulation of WNV has increased dramatically in recent years
throughout the Mediterranean basin, central and eastern Europe.
The emergence (Bakonyi et al., 2006) and quick dispersal (Valiakos
et al., 2011; Bakonyi et al., 2013) of a lineage (L)2 WNV strain in large
parts of Europe contributed signiﬁcantly to this development. Further-
more, the emergence of USUV in Italy in or before 1996 (Weissenböck
et al., 2013), in Austria in 2001 (Weissenböck et al., 2002), and its
subsequent expansion to Hungary, Switzerland, Germany, the Czech
Republic and Croatia has given additional cause for concern regarding
the impact of mosquito-borne ﬂaviviruses on human and animal
health in Europe (Vittecoq et al., 2013). Recent evidence of the
simultaneous occurrence of WNV- and USUV-associated human
neuroinvasive disease emerged in Croatia during the 2013 WNV
outbreak (Vilibic-Cavlek et al., 2014). While it is well recognized that
WNV infection poses a serious threat for human health, the clinical
importance of USUV is not yet fully understood due to its detection
only in sporadic cases of human infection (Vazquez et al., 2011; Pierro
et al., 2013). Although USUV dispersed quickly in central and southern
Europe following its emergence, very little is known about its
pathogenesis and activation of the innate immune response triggered
by USUV infection (Beck et al., 2013; Blázquez et al., 2013).
Monocyte-derived dendritic cells (DCs) are one of the major
producers of type I interferon (IFN) in response to ﬂavivirus infections
(Coccia, 2008), and they represent early targets of WNV infection
following the bite of an infected mosquito (Qian et al., 2011), providing
the virus with opportunities to manipulate DC functions as a means of
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evading host immunity. This manipulation of DC function is thought to
be important in WNV pathogenesis, although most of the molecular
mechanisms are currently unknown. While the importance of DCs in
WNV pathogenesis has been investigated (Samuel and Diamond, 2005;
Suthar et al., 2013), no such studies have been performed for USUV so
far. Interestingly, our previous study found that USUV was highly
sensitive to the antiviral actions of type I and III IFNs only when cells
were treated prior to but not after viral infection, suggesting that an
established USUV infection could overcome the antiviral effect of IFNs
as previously determined for WNV (Scagnolari et al., 2013).
Given the pivotal role played by DCs in the successful induction
of antiviral immune responses, we sought to determine whether
USUV and WNVs (L1 and L2) could productively infect DCs and
affect the expression of type I IFN. In particular, we determined the
activation rate of the response of IFN alpha subtypes and IFN-
stimulated genes (ISGs) in immature and mature DCs infected by
USUV and WNVs (L1 and L2, Fig. 1). Lastly, to determine the
potential role of type I and III IFNs in limiting USUV and WNV (L1
and L2) replication, we evaluated whether they differed in terms
of sensitivity/resistance to IFN antiviral actions.
Results
Characterization of single-growth curve replication of USUV and
WNVs (L1 and L2)
The growth kinetics of USUV and WNVs (L1 and L2) in immature
DCs are shown in Fig. 2. Each dot represents the mean value of three
separate experiments run in duplicate. As shown, all three viruses
analyzed were able to grow in immature DCs. In particular, a WNV L1
titer of 8.7 Log RNA copies/ml was recorded in cellular fraction 24 h p.
i., which peaked at approximately 9.6 Log RNA copies /ml between 48
and 72 h p.i. and decreased slowly after a further 12 and 24 h (Fig. 2).
Likewise, the WNV L2 titer reached 8.7 Log RNA copies/ml in cellular
fraction 24 h p.i. and peaked at approximately Log 9.5 RNA copies/ml
48 h p.i. The titer decreased slowly after another 24 and 48 h (Fig. 2).
TheWNV L2 titer was signiﬁcantly different from that of WNV L1 only
at 72 and 96 h p.i. (Fig. 2). In contrast, as far as the single-growth curve
replication of USUV is concerned, we found that the USUV replication
peak began earlier than that of the WNVs. In particular, USUV
exhibited a titer of 4.7 Log RNA copies/ml at 12 h p.i. that rose rapidly
to 5.5 Log RNA copies/ml after 24 h p.i.; over the next 24 and 48 h the
USUV titer declined as observed for WNVs (Fig. 2). Further, the RNA
copies of USUV measured on immature DCs at time of virus absorp-
tion (T0) and at 12, 24, 48, 72 and 96 h p.i. were signiﬁcantly fewer
than those observed for both WNVs (L1 and L2, Fig. 2).
Evaluation of IFN induction in DC cultures after USUV and WNVs (L1
and L2) infection
Having observed that USUV and WNVs (L1 and L2) titers
peaked in immature DCs between 12 and 48 h p.i., we determined
the time course and amount of IFN antiviral activity and IFN alpha
subtypes at different time points (12, 24, 48 h) p.i. The analysis
was performed at a MOI of 1–0.1–0.01 TCID50/cell.
The results showed that a signiﬁcant induction of IFN activity
can be recorded in immature DCs infected by USUV or WNVs at
most of the time points analyzed (Fig. 3). The only exception was
the lack of measurable IFN activity at 24 and 48 h p.i. in immature
DCs infected by both WNVs at a MOI of 1 TCID50/cell (Fig.3 Panel
A). We also observed that IFN activity in USUV-infected immature
DCs is greater than that induced by both WNVs (L1 and L2) at all
the MOI analyzed. Furthermore, WNV L2 induced a higher amount
of IFN activity than WNV L1 at 48 h p.i. (MOI¼0.1 TCID50/cell)
while the IFN activity in immature DCs did not differ between
WNV L1 and WNV L2 in all other conditions analyzed
(Fig. 3Panel A).
In addition, as shown in Fig. 3 (Panel A), reducing the MOI from
1 to 0.01 of TCID50/cell resulted in a greater induction of IFN
activity in USUV-infected immature DCs both at 24 and 48 h p.i. To
a lesser extent, the antiviral activity induced by WNVs also
increased with decreasing MOI.
Then we evaluated IFN activity in DCs induced to mature with
LPS 1 h p.i. with USUV and WNVs (L1 and L2) (Fig. 3 Panel B). We
found that LPS alone induced measurable IFN activity only at 12 h
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Fig. 1. Immature monocyte-derived dendritic cells (DCs) and those induced to mature with LPS stimulation. DCs were generated from peripheral blood CD14þ cells cultured
with GM-CSF and IL-4. On day 5 the resulting cells were 495% CD1aþ and CD14 . Immature DCs were left untreated, or stimulated with LPS (1 mg/ml). After 24 h incubation
DCs were stained with isotype control mAbs (dotted line) or with mAbs directed against indicated surface molecules. Thin and bold lines indicate ﬂuorescence distribution of
immature and mature DCs, respectively.
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Growth curves of USUV, WNV L1 and WNV L2 in DCs  
Fig. 2. Growth curves of Usutu virus (USUV), West Nile virus (WNV) lineage (L)1
and West Nile virus L2 in immature DCs. Initial infections were done at a MOI of
1 TCID50/cell. Aliquots of the cells (6105) were collected at the time of virus
adsorption (i.e. 90 min post infection [p.i.], time point 0) and at 4, 8, 12, 24, 48, 72,
and 96 h (h) p.i. Virus titers in the cellular fraction at each collection time were
determined using a TaqMan-based real-time RT-PCR technique for viral RNA
quantiﬁcation. Data are expressed as number of viral RNA copies/ml. Each dot
represents the mean7standard deviations of three separate experiments run in
duplicate. Mean values were compared using Student’s t-test. The replication
kinetics of USUV was signiﬁcantly different from that of WNVs (L1 and L2) where
indicated. Symbols for statistical comparison: nUSUV vs WNV L1 po0.05; §USUV vs
WNV L2 po0.05; 1WNV L1 vs WNV L2 po0.05.
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post treatment. Results indicated again that USUV induced more
IFN activity than LPS alone and WNVs (L1 and L2) at 12, 24, and
48 h p.i. (MOI of 1 TCID50/cell). Furthermore, more IFN activity was
also recorded in USUV-infected DCs at 24 and 48 h p.i compared to
those stimulated with LPS alone or infected with WNVs (L1 and
L2) at a MOI of 0.1 and 0.01 TCID50/cell (Fig. 3 Panel B). In contrast,
the IFN activity induced by USUV and WNVs (L1 and L2) were
lower than or similar to those induced by LPS alone in all other
conditions analyzed (Fig. 3 Panel B).
Next, we evaluated the IFN activity produced in the super-
natant of DCs pretreated for 24 h with LPS before WNVs (L1 and
L2) and USUV infections (Fig. 3 Panel C). We found that LPS alone
induced measurable IFN activity at 12, 24 and 48 h post treatment.
The results showed that USUV induced more IFN activity than both
WNVs (L1 and L2) at all analyzed conditions (Fig. 3 Panel C).
Furthermore, USUV induced similar (MOI 1 TCID50/cell) or higher
(MOI 0.1 and 0.01 TCID50/cell) levels of IFN activity than LPS alone
(Fig. 3 Panel C). There were no differences in terms of induction of
IFN activity between WNV L1 and WNV L2, although both these
viruses induced different levels of IFN activity in comparison to
LPS alone at a MOI 1 TCID50/cell (12, 24, 48 h p.i.) MOI 0.1 TCID50/
cell (24 and 48 h p.i) and MOI 0.01 (24 and 48 h p.i) Fig. 3 Panel C).
Evaluation of IFN alpha induction in DC cultures after USUV and
WNVs (L1 and L2) infections
Having observed that USUV had a tendency to induce a
stronger IFN activity than both WNVs (L1 and L2) in DCs, we
analyzed the IFN alpha subtype levels released by USUV- and
WNVs (L1 and L2)-infected DCs using ELISA.
The results indicated that IFN alpha subtype levels were
detectable in USUV-infected immature DCs and not in those
infected with both WNVs (L1 and L2) at a MOI of 1 TCID50/cell
(Fig. 4 Panel A). In particular, an approximately 4 Log fold increase
in IFN alpha subtype levels in DCs infected with USUV compared
to uninfected DCs (at all time points analyzed) was found at a MOI
of 1 TCID50/cell (Fig. 4 Panel A). The same results were also
observed at the other MOI of USUV infection analyzed (Fig. 4
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Fig. 3. Induction of interferon (IFN) activity after infection of immature and mature DCs obtained from six healthy donors with Usutu virus (USUV) and West Nile virus
(WNV) lineage (L)1 and WNV L2 at a MOI of 1-0.1-0.01 TCID50/cell. After 12, 24 and 48 h p.i., supernatants were collected and IFN antiviral activity was detected by biological
assay. The detection limit of biological assay was 5 laboratory units (LU)/ml. Control cell (CTR) in the bar graph indicates the uninfected immature DCs (Panel A). LPS in the
bar graphs indicates uninfected DCs stimulated with LPS (1mg/ml) alone for 1 h p.i. (Panel B) or 24 h before viral infection (Panel C). Panel A: Induction of IFN activity in DCs.
Panel B: Induction of IFN activity in DCs treated with LPS for 1 h p.i. Panel C: Induction of IFN activity in DCs pretreated with LPS. Data are expressed as mean
values7standard deviations of six separate experiments run in duplicate. Mean values were compared using Student's t-test. Values lower than the detection limit- of
detection of biological assay were considered 5 LU/ml for the statistical analysis. The analysis was performed using SPSS v.17.0 for Windows™. Symbols for statistical
comparison: nUSUV or WNV L1 or WNV L2 vs CTR (Panel A) or LPS (Panel B-C) po0.05; nnUSUV or WNV L1 or WNV L2 vs CTR (Panel A) or LPS (Panel B-C) po0.01; §USUV vs
WNV L1 po0.05; §§USUV vs WNV L1 po0.01; 1USUV vs WNV L2 po0.05; 11USUV vs WNV L2 po0.01; ¤WNV L1 vs WNV L2 po0.05.
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Panel A). On the other hand, WNVs (L1 and L2) induced similar
measurable levels of IFN alpha subtypes only at 48 h p.i. (MOI
0.1 and MOI 0.01 TCID50/cell) although the IFN alpha subtypes
were fewer than those induced by USUV (Fig. 4 Panel A).
Lastly, the results obtained by inducing maturation of DCs with
LPS 1 h p.i. with USUV and WNVs (L1 and L2) or pre-treating DCs
with LPS for 24 h before virus infection showed that only USUV
induced high levels of IFN alpha subtypes in contrast to both
WNVs (L1 and L2) or LPS alone (Fig. 4 Panel B and Panel C).
ISGs expression in DCs after USUV and WNVs (L1 and L2) infections
In order to establish whether USUV and both WNVs (L1 and L2)
affect the rate of type I IFN pathway activation, we evaluated the
mRNA levels of ISG56, ISG15 and HERC5 in immature DCs and
those treated with LPS (1 mg/ml) before (24 h) or 1 h p.i. with
USUV or WNVs (L1 and L2). This analysis was performed before
and 24 h p.i. (MOI of 1 TCID50/cell). We found that USUV and
WNVs (L1 and L2) induce similar ISG56 mRNA levels in immature
DCs (Fig. 5 Panel A). In contrast, ISG15 and HERC5 mRNA values
were higher in immature DCs infected with USUV compared to
those infected with WNVs (L1 and L2). We also found that DCs
treated with LPS (1 h) after USUV and WNVs (L1 and L2) infection
exhibited a signiﬁcant induction of all ISGs analyzed (Fig. 5 Panel
B). However, transcript levels of ISG56, ISG15 and HERC5 were
comparable in DCs treated with LPS (1 h) among USUV, WNV L1
and WNV L2 at 24 h p.i and were also similar to those produced
with LPS alone (Fig. 5 Panel B). In contrast, the ISG15 and HERC5
mRNAs were more expressed in DCs treated with LPS before (24 h)
infection with USUV than those infected with WNVs at the same
conditions while no differences were observed for ISG56 mRNA
levels (Fig. 5 Panel C). Lastly, ISGs expression in USUV or WNVs
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Fig. 4. Induction of interferon (IFN) alpha subtypes after infection of immature and mature DCs obtained from six healthy donors with Usutu virus (USUV), West Nile virus
(WNV) lineage (L)1 and WNV L2 at a MOI of 1-0.1-0.01 TCID50/cell. Levels of IFN alpha subtypes were detected at 12, 24 and 48 h p.i. by IFN alpha ELISA tests. Limit of
detection of ELISA tests were the 12.5 pg/ml. Control cell (CTR) in the bar graph indicates the uninfected immature DCs (Panel A). LPS in the bar graphs indicates uninfected
DCs stimulated with LPS (1mg/ml) alone for 1 h p.i. (Panel B) or 24 h before viral infection (Panel C). Panel A: Induction of IFN alpha subtypes in DCs. Panel B: Induction of IFN
alpha subtypes in DCs treated with LPS for 1 h p.i. Panel C: Induction of IFN alpha subtypes in DCs pretreated with LPS. Data are expressed as mean values7standard
deviations of six separate experiments run in duplicate. Mean values were compared using Student's t-test. Values lower than the detection limit of ELISA assay were
considered 12.5 pg/ml for statistical analysis. The analysis was performed using SPSS v.17.0 for Windows™. Symbols for statistical comparison: nUSUV or WNV L1 or WNV L2
vs CTR (Panel A) or LPS (Panel B-C) po0.05; nnUSUV or WNV L1 or WNV L2 vs LPS (Panel B-C) po0.01; §USUV vs WNV L1 po0.05; §§USUV vs WNV L1 po0.01; 1USUV vs
WNV L2 po0.05; 11USUV vs WNV L2 po0.01.
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infected DCs treated with LPS before (24 h) viral infection was
signiﬁcantly greater than that observed in unstimulated or LPS-
stimulated DCs (Fig. 5 Panel C).
Antiviral activity of type I and III IFN preparations against USUV and
WNVs (L1 and L2)
To further characterize the relationship among USUV, WNVs (L1
and L2) and type I and III IFN responses, we examined the antiviral
activities of IFN alpha2b, IFN beta, and IFN lambda 1–3 subtypes (0.5–
0.005 ng/ml) against USUV and WNVs (L1 and L2) at 48 h p.i. in the
A549 cell line. We found that pretreatment of A549 cells with type I
and III IFN preparations, signiﬁcally reduced USUV, WNV L1 andWNV
L2 replication (Fig. 6). However, we observed that the USUV yield
reduction obtained in A549 cells treated with IFN alpha, IFN beta, IFN
lambda1, IFN lambda2, IFN lambda3 was higher than that recorded for
both WNVs (L1 and L2) (Table 1). Furthermore the WNV L2 yield
reduction in type I IFN-treated A549 cells was higher than that of
WNV L1 (Table 1). In contrast, the viral yield reduction between WNV
L1 and L2 was comparable in IFN lambda 1–3 treated A549 cell
cultures at most of the conditions analyzed (Table 1).
Discussion
This study evaluated and compared the induction of type I IFNs
and ISGs expression in immature and mature DCs upon WNVs (L1
and L2) and USUV infection. The ﬁrst analysis conﬁrmed that both
WNVs (L1 and L2) infected and replicated in immature DCs (Davis
et al., 2006; Silva et al., 2007; Martina et al., 2008; Lim et al., 2010).
In particular, we found that both WNVs (L1 and L2) showed similar
in vitro growth kinetics in immature DCs, reaching the maximum
infectivity titer (9.6 (L1) and 9.5 (L2) Log RNA copies/ml) at the
same time point p.i. (48 h).
As far as USUV infection of DCs is concerned, the initial target
cell for this virus remains unknown. However, based on ﬁndings in
human infections with other ﬂaviviruses it is thought that USUV
ﬁrst infects Langerhans cells, the resident DCs of the skin, at the
site of inoculation, and the Langerhans cells then migrate to local
draining lymph nodes (Wu et al., 2000; Johnston et al., 2000).
Interestingly, here we provide evidence that exposure of immature
DCs to USUV leads to productive viral infection with the release of
high levels of IFN alpha suggesting that these cells may be early
targets for USUV infection as for other mosquito-borne ﬂaviviruses
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Fig. 5. Expression of interferon-stimulated genes (ISGs) at 24 h after infection of immature and mature DCs obtained from six healthy donors with Usutu virus (USUV), West
Nile virus (WNV) lineage (L)1 and WNV L2 at a MOI of 1 TCID50/cell. ISG expression was expressed as fold change (ΔΔCt method) using the equation 2- ΔΔCt. Panel
A: Expression of ISGs in DCs. Panel B: Expression of ISGs in DCs treated with LPS for 1 h p.i. Panel C: Expression of ISGs in DCs pretreated with LPS. Control cell (CTR) in the
bar graphs (Panels A–C) indicates unstimulated DCs (set to 1). LPS in the bar graphs (Panels B and C) indicates DCs stimulated with LPS (1 mg/ml) alone for 1 h p.i. (Panel B) or
24 h before viral infection (Panel C). Data are expressed as mean values7standard deviations of six separate experiments run in duplicate. nUSUV or WNV L1 or WNV L2 or
LPS vs CTR po0.05; nnUSUV or WNV L1 or WNV L2 or LPS vs CTR po0.01; ¤USUV or WNV L1 or WNV L2 vs LPS po0.05; §USUV vs WNV L1 po0.05; §§USUV vs WNV L1
po0.01; 1USUV vs WNV L2 po0.05; 11USUV vs WNV L2 po0.01;
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(Wu et al., 2000). However, although WNV L1, WNV L2 and USUV
had the same TCID50/viral RNA ratio, the amount of USUV RNA
measured in immature DCs was lower than that of both WNVs (L1
and L2), suggesting that USUV replication is less efﬁcient in
immature DCs than that of both WNVs (L1 and L2).
The different replication kinetics observed between USUV and
WNVs (L1 and L2) in DCs can in part be explained by the well-
established ability of WNV L1 to avoid the activation of IFN
regulatory factor 3 (IRF-3) during the early phase of infection
and trigger its activation and IFN production during the late stages
of infection when viral proteins are abundant (Keller et al., 2006).
WNV L1 (TX strain) can also block an inhibitor of the κB kinase ε
(IKKε)-dependent phosphorylation event on STAT1, resulting in a
temporal regulation of STAT1 phosphorylation and subsequent
expression of ISGs that are essential for the control of WNV
infection (Perwitasari et al., 2011). No studies have been per-
formed on the temporal activation of type I IFNs and/or JAK-STAT
signaling during USUV infection so far. However, we found that
besides the rapid replication peak of USUV in DCs, this virus
activates a greater antiviral response than both WNVs (L1 and L2),
suggesting that USUV could not block the early activation of IRF-3
and/or STAT1 phosphorylation. In addition, no differences were
observed in the induction of antiviral activity between the two
different lineages of WNV analyzed indicating that the strain
goshawk Austria 361/10 (L2) could interact with the innate
antiviral response in the same manner as WNV L1. In this regard,
Venter et al. (2005) reported that mice infected with seven strains
of WNVs (L1 and L2) exhibited different levels of IFNs, IFN-induced
proteins and IL-6 in their livers and spleens.
The lower induction of antiviral activity in WNV-infected DCs
than in those infected with USUV was also conﬁrmed by analyzing
the IFN alpha subtypes levels in immature DCs. Interestingly, no
detectable levels of IFN alpha subtypes were observed in immature
DCs infected with both WNVs (L1 and L2) at the highest MOI
analyzed. Therefore, the antiviral activity recorded in both WNVs
(L1 and L2)-infected immature DCs could be attributed to other
IFN subtypes (e.g. IFN beta or IFN lambda 1–3). In this regard,
Dafﬁs et al. (2008) reported that myeloid cells retain the ability to
produce IFN beta during WNV L1 (strain 3000.0259) infection
despite the lack of IRF-3 and IRF-7. Alternatively, other cytokines
exhibiting antiviral activities such as TNF alpha and IL-32 along-
side their inﬂammatory properties may be responsible for the
antiviral properties recorded in DCs infected with both WNVs (L1
and L2) strains (Steinke and Borish, 2006; Monteleone et al., 2014).
In contrast, immature DCs infected with WNVs at a MOI lower
than 1 (0.1 and 0.01 TCD50/cell) released detectable levels of IFN
alpha subtypes only at 48 h p.i., in accordance with the results
obtained from antiviral activity analysis. In agreement with the
above observations, Yeung et al., (2012) also detected measurable
quantities of IFN alpha in the supernatant of WNV L2-infected
monocyte-derived macrophages at 48 h p.i. It is also known that
WNV induction of IFN is replication dependent in DCs but that
type I IFN signaling is severely inhibited inside the cells when
replication of WNV is established (Silva et al., 2007; Guo et al.,
2005; Jones et al., 2005; Lin et al., 2004; Liu et al., 2006), thus
making infected cells an unlikely source of efﬁcient IFN production
via autocrine signaling (Liu et al., 2006). Conversely, early inhibi-
tion of IFN alpha induction by WNV allows the virus to spread
efﬁciently. As the number of WNV-infected cells increases, a
corresponding increase in IFN alpha production is detectable late
in infection (at 48 h p.i.), most likely due to its ampliﬁcation via
IFN receptor signaling in the surrounding non-infected cells (Liu
et al., 2006).
On the other hand, IFN alpha subtype levels released by DCs
after USUV infection at all MOI analyzed (1–0.01 TCID50/cell) were
higher than those measured in uninfected DCs. Furthermore, our
Table 1
Viral yield reduction of Usutu virus (USUV), West Nile virus (WNV) lineage (L) 1 and L2 in A549 cells treated with type I and III IFNs
Type of IFN (ng/ml) Virus yield reduction (Log)a p valuen
WNV L1 WNV L2 USUV WNV L1 vs WNVL2 WNV L1 vs USUV WNV L2 vs USUV
IFN alpha 0.5 1.570.09 270.08 2.570.17 o0.001 o0.001 o0.001
IFN alpha 0.05 1.270.18 1.770.15 2.370.18 o0.001 o0.001 o0.001
IFN alpha 0.005 0.570.06 1.170.08 1.570.12 o0.001 o0.001 o0.001
IFN beta 0.5 2.070.14 2.570.12 3.170.17 o0.001 o0.001 o0.001
IFN beta 0.05 1.2570.02 1.8670.09 2.570.15 o0.001 o0.001 o0.001
IFN beta 0.005 0.570.02 1.270.04 1.770.14 o0.001 o0.001 o0.001
IFN lambda1 0.5 1.170.03 1.6570.18 2.2570.12 o0.001 o0.001 o0.001
IFN lambda1 0.05 170.02 170.04 270.21 40.05 o0.001 o0.001
IFN lambda1 0.005 0.570.03 0.570.01 1.570.09 40.05 o0.001 o0.001
IFN lambda2 0.5 1.570.17 1.570.17 2.270.12 40.05 o0.001 o0.001
IFN lambda2 0.05 1.270.02 1.370.02 1.757 0.03 40.05 o0.001 o0.001
IFN lambda2 0.005 0.570.07 0.570.09 1.570.06 40.05 o0.001 o0.001
IFN lambda3 0.5 1.570.18 1.570.18 2.170.21 40.05 o0.001 o0.001
IFN lambda3 0.05 170.02 170.04 1.570.17 40.05 o0.001 o0.001
IFN lambda3 0.005 0.570.01 0.570.01 1.570.19 40.05 o0.001 o0.001
a Virus yield reduction [VIRUS TITER (CTR) – VIRUS TITER (þ IFN)].
n p values were evaluated using Student's t tests.
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Fig. 6. Evaluation of antiviral activity of type I and III IFN preparations against
USUV and WNVs (L1 and L2). Antiviral activity of IFN alpha2b, IFN beta, IFN lambda
1–3 were evaluated against USUV and WNVs (L1 and L2) in A549 cells. The titer of
each virus obtained from untreated cells, is indicated in the bar graph as “VIRUS”,
and types I and III IFNs treated cells (0.5 ng/mL, 0.05 ng/mL, and 0.005 ng/mL,
respectively) were determined using the Reed and Munch method. Every experi-
ment was done in triplicate. Mean values of 50% tissue culture infectious dose
(TCID50/ml) obtained from IFN-treated cells were compared to those obtained from
untreated cells using Student's t-test. Asterisk (*)in the bar graph shows the
signiﬁcant (po0.05) reduction of virus titer in IFN alpha2b, IFN beta, or IFN
lambda 1-3 treated cells compared to untreated cells (VIRUS).
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results analyzing the induction proﬁles of IFN-mediated antiviral
activity in mature DCs infected with WNVs (L1 and L2) indicate
that the two different lineages of WNV can reduce the levels of
LPS-induced IFN activity signiﬁcantly and in a similar manner. The
comparison between WNV (L1 strain NY99) and (L2 strain
goshawk Austria 361/10) in activating antiviral immunity inducing
IFN antiviral activity in mature DCs has not been reported to date.
It is noteworthy that the effects mediated by both WNVs on IFN
activity in DCs were particularly evident when cells were stimu-
lated with LPS 24 h before viral infection rather than 1 h p.i. These
results appear to be in line with the different IFN response
observed in DCs in relation to the duration of LPS treatment.
Indeed, we found that LPS treatment for 1 h induced a detectable
IFN activity only at 12 h post treatment whereas LPS treatment for
24 h stimulated a signiﬁcant production of IFN activity at all time
points analyzed. These ﬁndings could indicate that a short dura-
tion of LPS is not sufﬁcient to activate a signiﬁcant and prolonged
IFN response in DCs. Furthermore, no production of IFN alpha
subtypes was measured in mature DCs infected with WNVs (L1
and L2) at most of the conditions analyzed. Undetectable levels of
IFN alpha subtypes were also recorded in DCs stimulated for 1 or
24 h with LPS alone suggesting that the IFN activity measured
previously in mature DCs might be due to another type or subtype
of IFN (e.g. IFN lambdas or IFN beta, Coccia et al., 2004).
Interestingly, in contrast to WNVs, the levels of antiviral
activity and IFN alpha subtypes recorded in mature DCs infected
with USUV appeared to be higher than those induced by LPS.
Taken together these ﬁndings further support the hypothesis that
USUV could not evolve mechanisms that interfere with IFN
induction. Alternatively, as we previously found that USUV
induced lower levels of type I and III IFNs compared to vesicular
stomatitis virus, a well-known IFN-inducer (Scagnolari et al., 2004,
2011), these ﬁndings indicate that the ability of USUV to counter-
act IFN production may not be so efﬁcient than that of WNV.
As far as the induction of IFN recorded in DCs infected by WNV is
concerned, previous works indicate that while WNV (L1) was able to
inhibit IFN signaling (Wilson et al., 2008; Diamond, 2009), ISGs
expression is not completely suppressed during WNVs (L1 and L2)
infection (Hoover and Fredericksen, 2014). In agreement with pre-
vious studies, our results indicate that both WNVs (L1 and L2) can
induce ISGs in DCs but the rate of ISG activation may differ among
ISGs and ﬂaviruses. Indeed, both WNVs (L1 and L2) induced similar
levels of ISG56 compared to USUV, whereas lower levels of ISG15 and
HERC5 were recorded in WNV-infected immature DCs and in those
treated for 24 h with LPS before viral infections compared to those
induced by USUV. In contrast, these differences in the induction of
ISGs between USUV and WNVs (L1 and L2) were not appreciable
when DCs were stimulated with LPS for 1 h p.i. The lack of differences
in ISGs induction between USUV and WNVs (L1 and L2) was probably
due to a signiﬁcant upregulation of ISGs-mRNAs observed in unin-
fected DCs treated with LPS for 1 h compared to those stimulated with
LPS for 24 h. These ﬁndings suggest that the duration of LPS treatment
and the time of DC exposure to LPS (before or after viral infection)
might inﬂuence the magnitude of the ISGs response measured in
infected DCs with ﬂaviviruses.
Further studies are needed to evaluate the impact of LPS treatment
duration on the ISGs response in uninfected as well as viral-infected
DCs to examine whether USUV infection can activate a broader range
of pattern recognition receptors and related ISGs than WNVs. Con-
sidering that differential responses to IFN alpha subtypes have been
reported in terms of ISGs induction in DCs (Hilkens et al., 2003) there
is also an urgent need to determine the IFN alpha signature regulated
by USUV and WNVs (L1 and 2).
Besides the ability of USUV to trigger IFN induction and speciﬁc
ISGs production more efﬁciently than WNVs, we found that USUV is
more sensitive to the antiviral action of type I and III IFNs than both
WNVs (L1 and L2), providing further evidence that USUV and WNV
may interact differently with IFN antiviral defense programs of the
host cell. Furthermore, the responses to type I IFN antiviral action
seem to differ between WNVs (L1 and L2) as previously reported
(Keller et al., 2006). In particular, Keller et al. (2006) found that the
WNV L2 (strain Madagascar-AnMg798 MAD78) was more sensitive to
IFN than WNV L1 due to its ability to disrupt IFN-induced JAK-STAT
signaling, including the activation of Tyk2 and downstream phosphor-
ylation and nuclear translocation of STAT1 and STAT2. Interestingly, no
differences were found in terms of antiviral activity of IFN lambda 1-3
subtypes against WNV L1 andWNV L2, suggesting for the ﬁrst time to
our knowledge that the response of different WNV strains to the
antiviral action of IFNs can differ in relation to the type of IFN
considered. Otherwise the antiviral response associated with IFN
lambda 1-3 subtypes could be weaker than type I IFNs in the context
of human WNV infection.
Conclusion
Taken together our results indicate that USUV can replicate in DCs,
although USUV induces a higher activation of IFN-associated antiviral
immune response and is more sensitive to types I and III IFN than both
WNVs (L1 and L2). Thus, we could speculate that the rare association
of USUV with human diseases (Pecorari et al., 2009; Cavrini et al.,
2009) could be due to the inability of the virus to evade IFN-associated
innate immunity. Furthermore, the ability of WNV L2 (strain goshawk
Austria 361/10) to replicate in DCs and promote the induction of IFN
alpha subtypes and ISG responses, as well as the inhibition of IFN
lambda 1-3 did not differ from that of WNV L1, providing the ﬁrst
evidence that some WNV L2 strains could also interact with the IFN
response in the same way as WNV L1.
Material and methods
Viruses
USUV strain Vienna 2001-blackbird (GenBank accession no.
AY453411), WNV lineage 1 strain NY99 (GenBank accession no.
AF196835) and WNV lineage 2 strain goshawk Austria 361/10
(GenBank accession no. HM015884) were propagated and titrated
in Vero cells by determination of the 50% tissue culture infectious
dose (TCID50) per ml using Reed and Muench’s method (Reed and
Muench 1938).
Generation of monocyte-derived dendritic cells
Peripheral blood mononuclear cells (PBMC) from six healthy
donors were isolated over Ficoll-Hypaque gradients (lymphocyte
separation medium; MP Biomedicals, Aurora, OH, USA). The same
healthy donors were used for all the experiments reported in this
manuscript. Monocytes were positively selected from PBMC by an
immunomagnetic procedure using anti-CD14 conjugated microbeads
(Miltenyi Biotec, Calderara di Reno, Italy). Puriﬁed monocytes were
then cultured at 106 cells/ml in RPMI 1640 supplemented with 1 mM
sodium pyruvate, 0.1 mM nonessential amino acids, 2 mM l-gluta-
mine, 25 mM HEPES, 0.05 mM 2-ME, 100 U/ml penicillin, and 100 μg/
ml streptomycin (all from Life Technologies, Chagrin Falls, OH, USA)
supplemented with 10% fetal bovine serum, 100 ng/ml human rGM-
CSF (Leukine, Genzyme, Modena, Italy), and 100 ng/ml human rIL-4
(Immunotools GmbH, Friesoythe, Germany) at 37 1C with 5% CO2.
After ﬁve days of culture, this procedure yielded 495% pure CD1aþ
and CD14 immature DC preparations. Cells were extensively
washed and an aliquot was used to evaluate the single-growth curve
replication of WNVs and USUV and the IFN/ISG response after WNVs
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(L1 and L2) and USUV infection. At the same time, to evaluate the IFN/
ISGs response in USUV- and WNV-infected mature DCs, an aliquot of
immature DCs was also terminally differentiated by incubation with
1 mg/ml Escherichia.coli 055:B5 strain (Sigma-Aldrich, St. Louis, MO,
USA) for 24 h (Giardino Torchia et al., 2010) before or 1 h after (Pollara
et al., 2003) viral infection. All cell culture experiments were con-
ducted at 37 1C in a humidiﬁed 5% CO2 atmosphere.
Flow cytometry analysis of dendritic cells
Untreated or LPS-stimulated DCs were washed and then
incubated with ﬂuorochrome-conjugated mAbs in PBS containing
2% FBS for 30 min at 4 1C. Matched isotype mouse Igs were used in
control samples. Cells were acquired using a FACSCalibur ﬂow
cytometer and data analyzed using CellQuest software (Becton
Dickinson). Representative ﬂow cytometry plots of immature and
LPS-stimulated DCs are reported in Fig. 1.
Evaluation of single-growth curve replication of USUV and WNVs (L1
and L2)
USUV and WNVs (L1 and L2) infection of DCs (6105 cells/
well) was initiated by inoculation of the virus stocks at MOI of
1 TCID50/cell. The infectious unit: RNA copy ratio was 1 TCID50/ml:
107 RNA copies for USUV, WNVL1, and WNVL2. After 90 min of
adsorption, the USUV, WNV L1 and WNV L2 inocula were
removed, the cells washed and further cultured in 1 ml of RPMI
1640 (Invitrogen Corporation, San Diego, CA, USA) and 10% fetal
calf serum (FCS). Aliquots of the cells (6105) were collected at
the time of virus adsorption (i.e. 90 min post infection [p.i.]) and at
4, 8, 12, 24, 48, 72, and 96 h (h) p.i. WNV L1, WNV L2 and USUV
titers were determined using real-time RT-PCR as described below.
TaqMan-based real-time RT-PCR technique for USUV and WNVs (L1
and L2) detection
A TaqMan-based real-time RT-PCR technique for viral RNA quanti-
ﬁcationwas performed on immature DCs infected withWNVs (L1 and
L2) or USUV at a MOI of 1 TCID50/cell. Brieﬂy, RNAwas extracted using
QIAamp Viral RNA Mini Kit (Qiagen Spa, Milan, Italy). The RNA was
dissolved in Rnase-free water and viral RNA quantiﬁcation was
performed by Taqman assay after generation of cDNA using a High
Capacity cDNA Archive Kit (Applied Biosystems, Monza, Italy). The
primers and probe for ampliﬁcation of the partial NS5 gene of USUV
(Cavrini et al., 2011) or WNVs (L1 and L2) (Tang et al., 2006) were
added to the LightCycler 480 Probes Master mix (Roche, Milan, Italy)
at 300 and 200 nM, respectively, in a ﬁnal volume of 25 ml. The
standards for USUV and WNVs (L1 and L2) were obtained by cloning
73 bp of USUV NS5 or 93 bp of WNV NS5 gene into the pCR2.1
plasmid using a TOPO TA cloning kit (Invitrogen Corporation, San
Diego, CA, USA). A linear distribution (r¼0.99) was obtained between
101 and 109 copies of each NS5 (USUV or WNVs) standard. Data were
expressed as Log number of virus RNA (USUV or WNVs) copies/ml.
Evaluation of IFN activity (IFN bioassay)
IFN activity was determined at 12, 24 and 48 h p.i. with USUV and
WNVs (L1 and L2) in immature and mature DCs, evaluating the
reduction of cytopathic effect on A549 cell line by encephalomyocar-
ditis virus (EMCV). In brief, 3104 cells were seeded into each well of
96-well plates and incubated with threefold serial dilutions of super-
natant samples for 24 h at 37 1C. Following incubation, cells were
challenged with EMCV at MOI of 0.1 TCID50/cell and the plates were
incubated at 37 1C for 24 h. Virus-induced cytopathic effects were
assessed by microscopic examination. The cell monolayers were then
stained with crystal violet in 20% ethanol. The dye taken up by the
cells was eluted with 33% acetic acid and its absorbance measured at
580 nm with a microplate spectral scanning multimode reader
(Varioskans Flash Thermo Electron Corporation, Vantaa, Finland).
IFN concentrations were expressed as inverse dilution that provided
50% of cell protection against viral-induced cytopathic effect. The
lower limit of IFN activity detection of this assay was 5 laboratory
units (LU)/ml.
Evaluation of IFN alpha subtype levels
The IFN alpha subtypes in the supernatant of immature or
mature DCs infected with USUV and WNVs (L1 and L2) were
measured using an ELISA assay [human IFN alpha multi-subtype
ELISA kit (PBL interferon source, Piscataway, NJ, USA)], following
the manufacturer's instructions. The lower limit of detection of
this ELISA was 12.5 pg/ml for IFN alpha subtypes.
TaqMan-based real-time RT-PCR technique for mRNA expression
evaluation
mRNA levels of ISG15, ISG56, and HECT and RLD domain contain-
ing E3 ubiquitin protein ligase 5 (HERC5) were assessed by quantita-
tive real-time RT-PCR using the LightCycler480 instrument (Roche,
Basel, Switzerland). Brieﬂy, total RNA was extracted from uninfected
or WNV- (L1 and L2) and USUV-infected immature and mature DCs at
a MOI of 1 TCID50/cell using the TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer's protocol, and was reverse-
transcribed as previously described (Scagnolari et al., 2009). Primers
and probes for each gene were added to the Probes Master Mix
(Roche, Basel, Switzerland) at 500 and 250 nM, respectively, in a ﬁnal
volume of 20 μl. The housekeeping gene beta-glucuronidase was used
as an internal control. The sequences of the primers and probes used
for each gene were the following:
GUS: Forward 50- TCTGTCAAGGGCAGTAACCTG -30, Reverse 50-
GCCCACGACTTTGTTTTCTG -30, Probe 50-[6-carboxyﬂuorescein
(FAM)] TCAAGTTGGGAAGTGCGTCTTTTGGATG-C [tetramethylr-
hodamine (TAM)]n-30;
ISG15: Forward 50-TGGCGGGCAACGAATT-30, Reverse 50-
TGATCTGCGCCTTCA-30, Probe 50-[6FAM] TGAGCAGCTCCATGTC
[TAM]n-30;
ISG56: Forward 50-TGAAGAAGCTCTAGCCAACATGTC-30, Reverse 50-
GAGCTTTATCCACAGAGCCTTTTC-30, Probe 50[6FAM]TATGTCTTTC-
GATATGCAGCCAAGTTTTA-CCG[TAM]n-30 (Roche, Basel, Switz-
erland);
HERC5: assay on demand Hs00180943_m1 (Applied Biosys-
tems, Monza, Italy). The mRNA levels of ISG15, ISG56, and HERC5
were expressed as fold change (ΔΔCt method). Fold changes were
calculated by setting the uninfected cells as one.
Antiviral effect of types I and III IFN against USUV and WNVs (L1 and
L2) replication
A549 cells were seeded at 2.5104 cells per well in 96-well plates
using DMEM containing 10% FCS. After 24 h, cells were treated with
three different concentrations (0.5 ng/mL, 0.05 ng/mL, and 0.005 ng/
mL, respectively) of IFN alpha2b (Alfa Wassermann SpA, Bologna,
Italy), IFN beta (Rebif Merck-Serono, Darmstadt, Germany), IFN
lambda 1–2 (PBL interferon source, Piscataway, NJ, USA) and IFN
lambda 3 (R&D systems, Minneapolis, MN, USA) for 24 h. Every
experiment was done in triplicate. In each assay, 24 wells were ﬁlled
with 0.1 mL of DMEMwith 2% of FCS to serve as virus and cell control
(12 wells per control). After 24 h, each 96-well plates were then
washed and both IFN-treated wells and virus controls were inoculated
with USUV, WNV L1 and WNV L2 at MOI 1 TCID50/cell, respectively.
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After adsorption at 37 1C for 90 min, the viruses inocula were
removed, the cell monolayers were washed, and subsequently each
well was ﬁlled with 0.1 mL of MEM with 2% FCS. Cell culture controls
were cultivated simultaneously and treated in the same way as the
infected cultures except that DMEM with 2% FCS was used for
inoculation. At 48 h post infection culture supernatants of both IFN-
treated wells and virus controls were then collected and cells were
subjected to three consecutive freeze–thaw cycles at 80 1C. The
culture supernatants were then added to their respective cell lysate
and titrated for USUV, WNV L1 and WNV L2 yield on Vero cells. The
yields of each virus obtained at different concentrations of types I and
III IFNs were calculated by subtracting the viral titer obtained in
control cells from that obtained in IFN-treated cells.
Statistics
Data are expressed as mean values 7 standard deviations.
Mean values were compared using Student's t test; p values o0.05
were considered signiﬁcant. Analysis was performed with SPSS
v.17.0 for Windows.
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